Home » Drug Information » FDA Approved Drugs » 1997
Medical Areas: Endocrinology | Immunology | Pediatrics/Neonatology | Family Medicine | Infections and Infectious Diseases
View By:YearCompanyConditionsTherapeutic AreasDrug Names
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Bristol-Myers Squibb
Approval Status: Approved January 1997
Treatment Area: HIV
Zerit has been approved for the treatment of infants and
children infected with HIV. Zerit for Oral Solution is a
fruit-flavored powder in bottles providing 200mL of a 1mg/mL
stavudine solution upon constitution with water.
A number of clinical trials are underway to determine the safety
and efficacy of Zerit in combination with other HIV/AIDS
treatments, including nucleoside analogues and protease
In a recently completed AIDS Clinical Trials Group Study (ACTG
240), Zerit was compared with AZT for initial treatment of
HIV-infected children. Children receiving stavudine experienced
better weight gain, and their absolute CD4+ lymphocyte counts were
better maintained than children taking AZT. Subjects in the d4T
group encountered significantly fewer episodes of low white blood
cell counts compared to the AZT group.
Mechanism of Action
Zerit is a nucleoside analogue that inhibits the action of
reverse transcriptase, a vital enzyme the AIDS virus uses to
According to the Pediatric AIDS Foundation, an estimated 20,000
children nationwide are infected with HIV. More than 7,000 of these
children, under age 13, have AIDS, according to the U.S. Centers
for Disease Control and Prevention.